MedTrace Logo

Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage

NCT06194981 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2024-01-12

No results posted yet for this study

Summary

The goal of this retrospective study is to compare the efficacy and safety of 3-4 months to 5-6 months of CapOx/SOX adjuvant chemotherapy in pathological N3 gastric cancer patients.

Conditions

Interventions

DRUG

Oxaliplatin and capecitabine/ S-1 and capecitabine

Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA\<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA\>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1

Sponsors & Collaborators

  • The First Affiliated Hospital of Zhengzhou University

    lead OTHER

Principal Investigators

  • Hongyu Zhang, M.D. · The First Affiliated Hospital of Zhengzhou University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-11
Primary Completion
2024-03-28
Completion
2024-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06194981 on ClinicalTrials.gov